A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice

Vaccine. 2010 Nov 29;28(51):8085-94. doi: 10.1016/j.vaccine.2010.10.004. Epub 2010 Oct 16.


Dengue viruses co-circulate as four serologically distinct viruses (DENV1-4) that commonly infect individuals sequentially. Current DENV candidate vaccines incorporate the entire virion envelope E protein (E) ectodomain thereby stimulating both DENV serotype-specific and cross-reactive antibodies. Because the latter may enhance naturally acquired infection, such vaccine formulations must be tetravalent. We evaluated the neutralizing and enhancing antibody response to E domain III (dIII) proteins, in which serotype-specific neutralizing determinants are concentrated. Mice immunized with insect cell-secreted recombinant DENV-dIII proteins individually, and in tetravalent combination, produced serotype-specific IgG1 neutralizing antibodies that nevertheless exhibited measurable DENV enhancing activity in FcγR-bearing cells. Vaccine strategies directed to DENV-dIII-targeted neutralizing antibody production remain attractive but will likely require further modifications to induce safe, protective immunity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Blocking / blood*
  • Antibodies, Neutralizing / blood*
  • Antibodies, Viral / blood*
  • Dengue Vaccines / immunology*
  • Dengue Virus / immunology
  • Female
  • Immunoglobulin G / blood
  • Mice
  • Mice, Inbred BALB C
  • Vaccines, Subunit / immunology
  • Viral Envelope Proteins / immunology


  • Antibodies, Blocking
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Dengue Vaccines
  • Immunoglobulin G
  • Vaccines, Subunit
  • Viral Envelope Proteins